Depression is common in people with chronic kidney disease (CKD). When diagnosed via a gold standard semi-structured psychiatric interview by culturally-competent staff, depression affects one fifth to one quarter of people with CKD, whether in receipt of maintenance dialysis, with non-dialysis treated CKD, or with a functioning transplant (respective prevalence rates 22.8 (95% confidence interval (CI) 18.6 to 27.6)%, 21.4 (95%CI 11.1 to 37.2)% and 25.7 (95%CI 12.8 to 44.9)%) 1 . These frequencies are clearly in excess of the average population lifetime risk of ~ 9% 2 . Potential reasons for the high rates of depression in end stage kidney disease (ESKD) include the overlap of some risk factors for both conditions, the alteration of physiological processes associated with ESKD and the psychosocial consequences of living with ESKD 3 . Depression in people receiving dialysis is associated with lower quality of life, increased hospitalisations and, likely shortened survival 3 .
Despite its frequency and impact we have little evidence to guide management of depression in people with CKD. There are two Cochrane systematic reviews on antidepressant treatment 4 and psychosocial interventions 5 for depression in people on haemodialysis to guide practice.
Unfortunately, the psychosocial interventions review includes no trials. The antidepressant review includes one randomised, placebo-controlled trial (RCT) with depression as an endpoint. This trial of sertraline included only 43 participants 6 and showed a statistically significant lower Beck Depression Inventory (BDI) scale 7 mean score at the end of treatment in the sertraline group of -7.50 (95% CI -11.94 to -3.06). In one other trial 44 participants were randomised to receive citalopram or 'psychological training' and showed no differential evidence of benefit , recruiting only participants with sustained high scores over multiple assessments would identify those with the greatest need of intervention. However, this would shrink the eligible trial populations further.
Depression screening tools perform poorly in people receiving dialysis, in part, due to the overlapping constellation of symptoms common to depression and ESKD which include fatigue, altered sleep, and suppressed appetite. Depression screening tools were developed in general populations and were not designed to identify the cause of symptoms. A second reason may be the high rates of intermittent, distressing events that may appropriately elicit negative feelings. Just about every negative medical experience including cardiovascular events, cancer diagnoses, hospitalisations and impaired physical function are disproportionately higher among people with ESKD [16] [17] [18] . It is intriguing to note that a portion of those in SMILE 11 with high scores on the PHQ-9 refused depression treatment on the grounds of intercurrent events. Perhaps they 'knew' why they were experiencing a negative affect and were in effect refuting a diagnosis of endogenous depression. Lastly, people on dialysis experience substantial kidney disease-related losses, a phenomenon also associated with adverse scores on depression screening tools 19 .
These competing factors of high symptom burden, intercurrent events and kidney disease-related losses should not be dismissed purely as 'competing risks' for high scores on depression screening tools. The association between these events and psychiatrist-diagnosed depression has been demonstrated suggesting these events may be predisposing factors for depression 3, 19 . However, these competing factors do add to the complexity of identifying a 'pure' depression trial cohort as these papers illustrate. . Arguably, a safe, effective, low cost treatment for managing depression would realise a substantial and significant improvement in the lived experience.
